• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Burns - Pipeline Review, H2 2013 - Product Image

Burns - Pipeline Review, H2 2013

  • ID: 2686617
  • October 2013
  • 81 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Adocia
  • AlgiPharma AS
  • Birken GmbH
  • ConjuGon, Inc.
  • CytoTools AG
  • Destiny Pharma Ltd.
  • MORE

Burns - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Burns - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Burns.
- A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adocia
  • AlgiPharma AS
  • Birken GmbH
  • ConjuGon, Inc.
  • CytoTools AG
  • Destiny Pharma Ltd.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Burns Overview
Therapeutics Development
An Overview of Pipeline Products for Burns
Burns Therapeutics under Development by Companies
Burns Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Burns Therapeutics - Products under Development by Companies
Burns Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Burns Therapeutics Development
Hanall Pharmaceutical Co., Ltd.
CytoTools AG
Shenzhen Beike Biotechnology Co., Ltd.
ConjuGon, Inc.
Ventria Bioscience
TetraLogic Pharmaceuticals
Destiny Pharma Ltd.
NanoBio Corporation
USV Limited.
Adocia
Fibrocell Sciences, Inc.
Se-cure Pharmaceuticals Ltd.
AlgiPharma AS
Birken GmbH
Burns - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Neu-2000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Necrostatin Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azficel-T - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
StrataGraft Skin Tissue - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OleogelS-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amnion Derived Cellular Cytokine Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Burns - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-156Fib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARA-290 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
B-4474 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Optibumin Biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Humam Serum Albumin Biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Silver-Enzyme Hybrid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XF-70 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fibroblast Growth Factor Conjugate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xib-1302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-2248 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Burns Therapeutics - Drug Profile Updates
Burns Therapeutics - Discontinued Products
Burns Therapeutics - Dormant Products
Burns - Product Development Milestones
Featured News & Press Releases
Aug 29, 2013: Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of Four Lots of Cubicin 500Mg in 10Ml Single Use Vials Due to Presence of Particulate Matter
Jul 02, 2013: Fibrocell Science Extends Patent Protection for LAVIV Through 2031
Dec 17, 2012: Fibrocell To Initiate Phase II Clinical Trial Of azficel-T For Restrictive Burn Scars
Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva
Dec 08, 2010: DPT Receives FDA Approval To Commercially Manufacture Collagenase SANTYL Sterile Ointment
Oct 12, 2010: Nanobio And The University Of Michigan Awarded $1.5M Department Of Defense Grant To Study Topical Anti-Infective Treatment For Combat Related Injuries
Sep 14, 2009: NanoBio Presents Key Data On The Use Of Nanoemulsions To Treat Burn Wound Infections
Aug 12, 2009: Kuros Announces Encouraging Phase IIa Data With KUR-212 In Patients With Burns Requiring Mesh Grafting
Aug 11, 2008: Kuros Announces Results Of One-Month Follow-Up Of Phase IIa Trial Of KUR-212 In Patients With Burns Requiring Mesh Grafting
Feb 04, 2008: Kuros Completes Patient Recruitment In Phase Lia Trial Of KUR 212 In Patients With Severe Burns Requiring Meshed Skin Grafting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Burns, H2 2013
Products under Development for Burns - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Hanall Pharmaceutical Co., Ltd., H2 2013
CytoTools AG, H2 2013
Shenzhen Beike Biotechnology Co., Ltd., H2 2013
ConjuGon, Inc., H2 2013
Ventria Bioscience, H2 2013
TetraLogic Pharmaceuticals, H2 2013
Destiny Pharma Ltd., H2 2013
NanoBio Corporation, H2 2013
USV Limited., H2 2013
Adocia, H2 2013
Fibrocell Sciences, Inc., H2 2013
Se-cure Pharmaceuticals Ltd., H2 2013
AlgiPharma AS, H2 2013
Birken GmbH, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Burns Therapeutics - Drug Profile Updates
Burns Therapeutics - Discontinued Products
Burns Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Burns, H2 2013
Products under Development for Burns - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 39

Note: Product cover images may vary from those shown

Hanall Pharmaceutical Co., Ltd.
CytoTools AG
Shenzhen Beike Biotechnology Co., Ltd.
ConjuGon, Inc.
Ventria Bioscience
TetraLogic Pharmaceuticals
Destiny Pharma Ltd.
NanoBio Corporation
USV Limited.
Adocia
Fibrocell Sciences, Inc.
Se-cure Pharmaceuticals Ltd.
AlgiPharma AS
Birken GmbH

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos